Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

Blood

Volumn 118, Issue 17, 2011, Pages 4567-4576

  Cortes, Jorge E ^a   Kantarjian, Hagop M ^a   Brümmendorf, Tim H ^b,c   Kim, Dong Wook ^d   Turkina, Anna G ^e   Shen, Zhi Xiang ^f   Pasquini, Ricardo ^g   Khoury, H Jean ^h   Arkin, Steven ⁱ   Volkert, Angela ⁱ   Besson, Nadine ⁱ   Abbas, Richat ⁱ   Wang, Junyuan ⁱ   Leip, Eric ⁱ   Gambacorti Passerini, Carlo ^j  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d The Catholic University of Korea   (South Korea)

^e NATIONAL RESEARCH CENTER FOR HEMATOLOGY   (Russian Federation)

^f SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^g FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^h EMORY UNIVERSITY   (United States)

ⁱ PFIZER INC   (United States)

^j UNIVERSITY OF MILANO BICOCCA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BOSUTINIB; IMATINIB;

ADULT; AGED; ANEMIA; ARTICLE; CANCER REGRESSION; CHEMOTHERAPY INDUCED EMESIS; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DIARRHEA; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; OVERALL SURVIVAL; PANCYTOPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 80055070888     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-05-355594     Document Type: Article

References (38)

1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Chronic Myelogenous Leukemia. V. 2.2009. http://www.nccn.org/ professionals/physician-gls/PDF/cml.pdf. Accessed May 12, 2009.
2. American Cancer Society. Cancer Facts & Figures, 2010. Atlanta, GA: American Cancer Society; 2010.
3. Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007;110(10):3540- 3546. (Pubitemid 350159618)
4. Hochhaus A, Baccarani M, Deininger M, et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia. 2008;22(6):1200- 1206. (Pubitemid 351833788)
5. de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol. 2008;26(20):3358- 3363.
6. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354(24):2531- 2541. (Pubitemid 43882349)
7. Hochhaus A, Kantarjian HM, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 2007;109(6):2303-2309. (Pubitemid 46425867)
8. Kantarjian H, Pasquini R, Hamerschlak N, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood. 2007;109(12):5143-5150. (Pubitemid 46890528)
9. Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol. 2008;26(19):3204-3212.
10. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006;354(24):2542-2551. (Pubitemid 43882350)
11. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994-1004. (Pubitemid 36302244)
12. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408-2417. (Pubitemid 44903745)
13. Ramirez P, Dipersio JF. Therapy options in imatinib failures. Oncologist. 2008;13(4):424-434. (Pubitemid 351679922)
14. Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer. 2007;7(5):345-356. (Pubitemid 46652483)
15. Kantarjian H, Pasquini R, Levy V, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer. 2009;115(18):4136-4147.
16. Kantarjian HM, Giles FJ, Bhalla KN, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood. 2011;117(4):1141-1145.
17. Puttini M, Coluccia AM, Boschelli F, et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res. 2006;66(23):11314-11322. (Pubitemid 46009962)
18. Golas JM, Arndt K, Etienne C, et al. SKI-606, a 4-anilino-3- quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res. 2003;63(2):375-381. (Pubitemid 36152495)
19. Remsing Rix LL, Rix U, Colinge J, et al. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia. 2009;23(3):477-485.
20. Konig H, Holyoake TL, Bhatia R. Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606. Blood. 2008;111(4):2329-2338. (Pubitemid 351451441)
21. Bartolovic K, Balabanov S, Hartmann U, et al. Inhibitory effect of imatinib on normal progenitor cells in vitro. Blood. 2004;103(2):523-529. (Pubitemid 38140082)
22. Redaelli S, Piazza R, Rostagno R, et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol. 2009;27(3):469-471.
23. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108(6):1809-1820. (Pubitemid 44394987)
24. Kantarjian HM, Giles F, Bhalla KN, et al. Nilotinib in chronic myeloid leukemia patients in chronic phase (CMLCP) with imatinib resistance or intolerance: 2-year follow-up results of a phase 2 study. Blood. 2008;112(suppl):Abstract 3238.
25. Quintás-Cardama A, Han X, Kantarjian H, Cortes J. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood. 2009;114(2):261-263.
26. Newman DK. The Y's that bind: negative regulators of Src family kinase activity in platelets. J Thromb Haemost. 2009;7(suppl 1):195-199.
27. Gratacap MP, Martin V, Valera MC, et al. The new tyrosine-kinase inhibitor and anti-cancer drug dasatinib reversibly affects platelet activation in vitro and in vivo. Blood. 2009;114(9):1884-1892.
28. Brave M, Goodman V, Kaminskas E, et al. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin Cancer Res. 2008;14(2):352-359. (Pubitemid 351226100)
29. Scheinfeld N. Imatinib mesylate and dermatology part 2: a review of the cutaneous side effects of imatinib mesylate. J Drugs Dermatol. 2006;5(3):228-231.
30. Quintás-Cardama A, Kantarjian H, O'Brien S, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol. 2007;25(25):3908-3914. (Pubitemid 47477268)
31. Gora-Tybor J, Robak T. Targeted drugs in chronic myeloid leukemia. Curr Med Chem. 2008;15(29):3036-3051.
32. SPRYCEL (dasatinib) tablet for oral use [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2009.
33. GLEEVEC (imatinib mesylate) tablets for oral use [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2009.
34. Franceschino A, Tornaghi L, Benemacher V, Assouline S, Gambacorti-Passerini C. Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib. Haematologica. 2008;93(2):317-318. (Pubitemid 351397728)
35. Abbas R, Hug B, Leister C, Burns J, Sonnichsen D. Asingle dose, crossover, placebo- and moxifloxacin-controlled study to assess the effects of bosutinib (SKI-606) on cardiac repolarization in healthy adult subjects. Poster presented at the 15th Congress of the European Hematology Association; June 12, 2010; Barcelona, Spain:Abstract 0846.
36. Tasigna (nilotinib) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2007.
37. le Coutre P, Ottmann OG, Giles F, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood. 2008;111(4):1834-1839. (Pubitemid 351451490)
38. Keller G, Schafhausen P, Brummendorf TH. Bosutinib: a novel dual Src/Abl kinase inhibitor. In: Martens UM, ed. Small Molecules in Oncology, Recent Results in Cancer Research. Vol 184. Berlin, Germany: Springer Verlag; 2010.